BGJ398 (Infigratinib): Mechanism of Action

BGJ398 (Infigratinib) MOA:Targeting FGFR2/MAPK for Cholangiocarcinoma

🎯 check BGJ398 (Infigratinib) product page

BGJ398 (Infigratinib) is a selective, reversible ATP-competitive pan-FGFR inhibitor. It blocks MAPK/ERK and PI3K/AKT/mTOR signaling by inhibiting FGFR phosphorylation, effectively suppressing tumor cell proliferation, migration, and inducing apoptosis.

Primary Applications and Mechanism of Action